These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 31642769)
1. Novel Antibacterial Strategies for Combating Bacterial Multidrug Resistance. Xu XL; Kang XQ; Qi J; Jin FY; Liu D; Du YZ Curr Pharm Des; 2019; 25(44):4717-4724. PubMed ID: 31642769 [TBL] [Abstract][Full Text] [Related]
2. Efflux Pump Inhibitors: A Novel Approach to Combat Efflux-Mediated Drug Resistance in Bacteria. Wang Y; Venter H; Ma S Curr Drug Targets; 2016; 17(6):702-19. PubMed ID: 26424403 [TBL] [Abstract][Full Text] [Related]
3. Current Advances in Developing Inhibitors of Bacterial Multidrug Efflux Pumps. Mahmood HY; Jamshidi S; Sutton JM; Rahman KM Curr Med Chem; 2016; 23(10):1062-81. PubMed ID: 26947776 [TBL] [Abstract][Full Text] [Related]
4. Emergence of a Potent Multidrug Efflux Pump Variant That Enhances Campylobacter Resistance to Multiple Antibiotics. Yao H; Shen Z; Wang Y; Deng F; Liu D; Naren G; Dai L; Su CC; Wang B; Wang S; Wu C; Yu EW; Zhang Q; Shen J mBio; 2016 Sep; 7(5):. PubMed ID: 27651364 [TBL] [Abstract][Full Text] [Related]
5. The development of efflux pump inhibitors to treat Gram-negative infections. Blanco P; Sanz-García F; Hernando-Amado S; Martínez JL; Alcalde-Rico M Expert Opin Drug Discov; 2018 Oct; 13(10):919-931. PubMed ID: 30198793 [TBL] [Abstract][Full Text] [Related]
6. [Efflux pumps: their role in Staphylococcus aureus antibiotic resistance]. Doléans-Jordheim A; Michalet S; Bergeron E; Boisset S; Souard F; Dumontet C; Dijoux-Franca MG; Freney J Ann Biol Clin (Paris); 2008; 66(5):499-508. PubMed ID: 18957338 [TBL] [Abstract][Full Text] [Related]
7. Alkylaminoquinolines inhibit the bacterial antibiotic efflux pump in multidrug-resistant clinical isolates. Malléa M; Mahamoud A; Chevalier J; Alibert-Franco S; Brouant P; Barbe J; Pagès JM Biochem J; 2003 Dec; 376(Pt 3):801-5. PubMed ID: 12959639 [TBL] [Abstract][Full Text] [Related]
8. Role of bacterial efflux pumps in biofilm formation. Alav I; Sutton JM; Rahman KM J Antimicrob Chemother; 2018 Aug; 73(8):2003-2020. PubMed ID: 29506149 [TBL] [Abstract][Full Text] [Related]
9. Efflux pumps: their role in antibacterial drug discovery. Lomovskaya O; Watkins WJ Curr Med Chem; 2001 Dec; 8(14):1699-711. PubMed ID: 11562289 [TBL] [Abstract][Full Text] [Related]
11. Bacterial resistance to antibiotics: active efflux and reduced uptake. Kumar A; Schweizer HP Adv Drug Deliv Rev; 2005 Jul; 57(10):1486-513. PubMed ID: 15939505 [TBL] [Abstract][Full Text] [Related]
12. Bacterial Multidrug Efflux Pumps of the Major Facilitator Superfamily as Targets for Modulation. Kumar S; He G; Kakarla P; Shrestha U; Ranjana KC; Ranaweera I; Willmon TM; Barr SR; Hernandez AJ; Varela MF Infect Disord Drug Targets; 2016; 16(1):28-43. PubMed ID: 27052334 [TBL] [Abstract][Full Text] [Related]
13. Inhibitors of multidrug resistant efflux systems in bacteria. Zechini B; Versace I Recent Pat Antiinfect Drug Discov; 2009 Jan; 4(1):37-50. PubMed ID: 19149695 [TBL] [Abstract][Full Text] [Related]
14. Multidrug resistant Acinetobacter baumannii--the role of AdeABC (RND family) efflux pump in resistance to antibiotics. Wieczorek P; Sacha P; Hauschild T; Zórawski M; Krawczyk M; Tryniszewska E Folia Histochem Cytobiol; 2008; 46(3):257-67. PubMed ID: 19056528 [TBL] [Abstract][Full Text] [Related]
15. Conessine as a novel inhibitor of multidrug efflux pump systems in Pseudomonas aeruginosa. Siriyong T; Srimanote P; Chusri S; Yingyongnarongkul BE; Suaisom C; Tipmanee V; Voravuthikunchai SP BMC Complement Altern Med; 2017 Aug; 17(1):405. PubMed ID: 28806947 [TBL] [Abstract][Full Text] [Related]
16. Multidrug Resistance in Neisseria gonorrhoeae: Identification of Functionally Important Residues in the MtrD Efflux Protein. Chitsaz M; Booth L; Blyth MT; O'Mara ML; Brown MH mBio; 2019 Nov; 10(6):. PubMed ID: 31744915 [TBL] [Abstract][Full Text] [Related]
17. Multidrug efflux pumps and their role in antibiotic and antiseptic resistance: a pharmacodynamic perspective. Alibert S; N'gompaza Diarra J; Hernandez J; Stutzmann A; Fouad M; Boyer G; Pagès JM Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):301-309. PubMed ID: 27764576 [TBL] [Abstract][Full Text] [Related]
18. Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use. Lomovskaya O; Bostian KA Biochem Pharmacol; 2006 Mar; 71(7):910-8. PubMed ID: 16427026 [TBL] [Abstract][Full Text] [Related]
19. Designing drugs that overcome antibacterial resistance: where do we stand and what should we do? Penchovsky R; Traykovska M Expert Opin Drug Discov; 2015 Jun; 10(6):631-50. PubMed ID: 25981754 [TBL] [Abstract][Full Text] [Related]
20. The challenges and applications of nanotechnology against bacterial resistance. Lei Z; Karim A J Vet Pharmacol Ther; 2021 May; 44(3):281-297. PubMed ID: 33277732 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]